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Improvements in chemotherapy for some malignancies,
such as childhood leukaemia, have resulted in consider-
able increases in survival. However, many of the more
common adult cancers, including carcinoma of the breast,
remain stubbornly resistant to drug treatment, despite
dose escalation and the increasing use of stem cell
support [1]. The explosion of interest in apoptosis in the
past 10 years has been underpinned by the hope that a
greater understanding of the way in which cancer cells die
after chemotherapy-induced damage would allow the
development of a more rational approach to overcoming
the problem of drug resistance. Unless cells receive exter-
nal survival signals, they will ‘default’ to apoptosis [2].
These signals are provided by soluble cytokines and
growth factors, cell–extracellular matrix contact and
cell–cell contact. The overall survival threshold is probably
determined by the balance of interactions between
members of the Bcl-2 family of proteins on the cytoplas-
mic surface of internal membranes, such as the outer
mitochondrial membrane. These pro-apoptotic or anti-
apoptotic proteins can homodimerise or heterodimerise,
and a satisfying but still unproven hypothesis is that, by
doing so, they either activate or neutralise each other
depending on the balance of death and survival stimuli.
A wide range of chemotherapeutic agents is able to trigger
apoptosis (reviewed in [3]). In this model of their action,
chemotherapeutic drugs drive cell death by generating
damage signals at their locus of action (eg DNA damage),
and these signals become integrated at Bcl-2 family protein
containing complexes where the decision to undergo apop-
tosis is taken and signalled to apoptosis effector molecules.
This is classical stimulus response coupling, and it is the
efficiency of this coupling that determines the threshold for
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survival. A complex of proteins, describing this coupling
and activation centre, has been conceptualised as an
‘apoptosome’, and contains the precursors of the prote-
olytic enzymes (caspases) that cleave key cellular proteins
to generate the apoptotic morphology [4]. While many
mechanisms of drug resistance have been defined in which
drug–target interactions are modified, it is also important to
consider the impact of the cellular environment on the cou-
pling of drug-induced damage to the activation of the
‘apoptosome’, via modification of Bcl-2 family proteins.
Cell survival in vivo depends on ligation of surface recep-
tors by soluble factors and both cell–cell and cell–matrix
interactions. The signalling pathways activated by these
receptors ultimately impinge upon Bcl-2 family members,
and this may be a key mechanism mediating drug resis-
tance. Such a survival signalling pathway exists between
interleukin (IL-3) receptor ligation and the pro-apoptotic
protein Bad [5]. It is thus possible that signals from growth
factors and cytokines provide not only mitogenic cues, but
also discrete survival signals that raise the survival thresh-
old of tumours and contribute to drug resistance. Loss of
IL-3 in pro-B lymphocytes leads to the upregulation of the
pro-apoptotic Bcl-2 family protein Bim, via the Forkhead
transcription factor FKHL-1, and this induces apoptosis [6].
In a B-cell lymphoma model, the provision of extrinsic sur-
vival signals attenuates etoposide-induced exposure of the
N-terminus of Bax, an early step in the activation of this pro-
apoptotic protein [7]. In the mouse mammary epithelial cell
model, loss of cell–substrate contact-mediated ligation of
integrin receptors results in a conformational change in the
N-terminus of Bax, and its subsequent translocation to the
mitochondria [8]. These conformational changes in Bax,
and its subsequent translocation to mitochondria, are medi-
ated by p38 mitogen activated protein (MAP) kinase in
nitric oxide induced apoptosis in neurons [9]. A further link
between protein serine/threonine kinase signalling and this
part of the cell death response is provided by the recent
observation that c-Jun N-terminal kinase (JNK) is involved in
the coupling of DNA damage to mitochondrial cytochrome c
release in fibroblasts [10].
This brings us neatly from the general concepts of apopto-
sis and cell survival to the specific roles of the extracellular
signal-related kinase (ERK)/MAP kinase family of protein
kinases in the regulation of cell death. This family of
kinases consists of proline-directed serine/threonine
kinases that are activated by dual phosphorylation on tyro-
sine and threonine, and that are widespread among living
organisms. In mammals, they exist mainly in cascades con-
taining three kinases functioning in series. In broad terms,
there are three distinct families. In the ERK1/ERK2
module, growth factor derived extracellular signals are
translated to Raf-1 activation, which leads to the phospho-
rylation of MAP kinase kinase (MEK)1 and MEK2; these in
turn phosphorylate and activate ERK1 and ERK2. In the
stress-activated protein kinase/JNK module, a wide range
of stimuli including UV light and osmotic shock result in
activation of MEK kinase (MEKK)1, and then MAP kinase
kinase (MKK)4 and MKK7, which phosphorylate JNK. The
final member of the family is p38 MAP kinase, which is
also activated by stress and inflammatory cytokines such
as tumour necrosis factor-a and IL-1, MEKK1 and MKK3
and MKK4 (for a review, see [11]). Although these path-
ways share many similarities, they are clearly independent:
MEK1/MEK2 do not phosphorylate JNK or p38, and
MKK3/MKK4/MKK7 do not phosphorylate ERK1/ERK2
[12]. A widely accepted model is that the balance
between growth factor activated ERK and stress-activated
JNK and p38 pathways determines whether the cell lives
or dies. In the rat phaeochromcytoma cell line PC-12,
withdrawal of nerve growth factor leads to sustained JNK
and p38 MAP kinase activity, inhibition of ERK activity,
and apoptosis, which can be prevented by transfection of
constitutively active MEK1 mutants [13]. Hippocampal
neurons in jnk 3 knockout mice do not undergo excitoxin-
induced apoptosis [14], and JNK is needed for apoptosis
of immature T lymphocytes in developing mice [15]. JNK is
also needed for UV-induced apoptosis in mouse fibro-
blasts, which intriguingly is mediated via a failure of mito-
chondrial cytochrome c release, suggesting further
interaction between the Bcl-2 family and the MAP kinase
signalling cascades [10]. Further subtlety is lent to this
system by the discovery that, while MEKK1–/– embryonic
stem cell lines lose their JNK response to microtubule dis-
ruption and cold shock, this kinase is not needed for JNK
activation by UV irradiation or heat shock [16]. Further-
more, this loss of MEKK1-mediated activation of JNK
leads to an increased apoptotic response to hyper-
osmolarity and microtubule disruption, suggesting that the
survival or death specificity of these pathways may
depend upon the precise nature of the signal inducing
them. JNK does not appear to be needed for Fas-medi-
ated or tumour necrosis factor-mediated apoptosis [17]
and, in some situations, may protect cells from apoptosis.
The discovery of small molecule inhibitors of the MAP
kinase pathways facilitated the transition from the theoreti-
cal framework already described to the implementation of
novel therapies. The first inhibitor to be identified was
PD 098059, which inhibits MEK without affecting JNK or
p38, and is able to prevent call growth and reverse the
phenotype of ras-transformed cells [18]. U0126 is a
further non-competitive MEK1/MEK2 inhibitor, which is
also specific for these kinases. The major advantage of
U0126 over PD 098059 is its 100-fold greater affinity for
MEK, thus making it more suited to in vivo applications
[19]. The efficacy of this approach has been demon-
strated  in vivo with an even more effective MEK inhibitor,
PD 184352. This compound is able to completely inhibit
MEK activity in a range of human tumour cell lines at con-
centrations as low as 100 nM, without effecting JNK orBreast Cancer Research    Vol 3 No 3 Makin and Dive
p38 activity. This compound was active in vivo against
xenografts from a range of tumour cell lines, its activity cor-
relating with the expression levels of MEK within the cell
lines [20]. This overexpression of MEK within experimen-
tally induced tumours has also been demonstrated in vivo
in certain types of brain tumours and, pertinently, in breast
carcinoma [21]. Thus, not only is the theoretical basis for
the use of MEK inhibition to modulate survival signalling in
place but effective drugs are available, and the target is
overexpressed in breast cancer. But with which
chemotherapeutic drugs should these inhibitors be used?
The alkaloid drug paclitaxel (Taxol) is a relatively novel anti-
cancer agent. Paclitaxel has a wide range of activities in
vivo against relatively drug-resistant solid tumours and a
unique mode of action. Unlike the Vinca alkaloids, pacli-
taxel binds preferentially to polymerised tubulin and shifts
the dynamic balance between tubulin dimers and micro-
tubules towards microtubule assembly. Paclitaxel ulti-
mately causes mitotic block at the metaphase/anaphase
boundary by the suppression of dynamic instability (the
transition between phases of lengthening and shortening)
at the ends of mitotic spindle microtubules [22]. Paclitaxel
treatment of lymphoblasts in culture results in a rapid
increase in JNK activity and a reduction in ERK2 activity
[23]. Bcl-2 can also be phosphorylated by JNK [24], pro-
viding a further link between paclitaxel, MAP kinase cas-
cades and Bcl-2 family proteins. The in vivo significance
of these observations remains to be clarified.
MacKeigan et al [25] have used the theoretical framework
discussed in this paper to augment the pro-apoptotic
activity of paclitaxel in breast, lung and ovarian carcinoma
cell lines. They show that treatment with nanomolar con-
centrations of paclitaxel results in increases in JNK and
ERK1/ERK2 activity, and that the latter is specifically
blocked by micromolar concentrations of the MEK
inhibitor U0126. Paclitaxel-induced apoptosis is signifi-
cantly increased by U0126, PD98059, or by dominant-
negative MEK, and this effect is considerably more than
additive. This logical approach to the modulation of drug-
induced apoptosis is exactly what was hoped would arise
from an understanding of cell death, illustrating well the
principle that apoptosis results from either loss of survival
signals (provided in this setting by ERKs) or death signals
(in the present study from JNK). The power of the
approach of MacKeigan et al [25] is partly that it tilts both
sides of the balance, both activating death signals and
inhibiting survival signals, but that they are also able to
demonstrate that clinically relevant concentrations of drug
can be made dramatically more potent with readily avail-
able agents. With the in vivo efficacy of small molecule
MAP kinase inhibitors already demonstrated, their use to
enhance the efficacy of chemotherapeutic agents in clini-
cal trials is a realistic goal. Perhaps the future of
chemotherapy is no longer so bleak.
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